Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | CheckMate 9KD: finding novel drug combinations for patients in all stages of treatment

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Karim Fizazi, MD, PhD, of the University of Paris-Sud, Orsay, France, presents the objectives and motivations behind the CheckMate 9KD trial (NCT03338790). This trial investigated nivolumab in combination with either rucaparib, docetaxel or enzalutamide in men with castration-resistant metastatic prostate cancer. Prof. Fizazi highlights how this trial was created to help find novel drug combinations that could be given to different patients.